The core of the authors’ argument is that losing lean mass is not the same thing as losing functional muscle. When any person loses weight, whether through diet, surgery, or medication, the body sheds both fat and lean tissue because a lighter body simply demands less structural and metabolic support. A recent meta-analysis cited in the perspective found that lean mass accounted for roughly 25 to 39 percent of the total weight lost with incretin-based therapies, a proportion broadly comparable to the 26.2 percent observed with conventional lifestyle interventions. In other words, the fraction of weight loss coming from lean tissue during pharmacotherapy looks remarkably similar to what happens when patients lose weight the old-fashioned way, suggesting that the phenomenon reflects physiological body composition remodeling rather than a drug-specific pathology.

Real-world comparative data strengthen this interpretation considerably. In a cohort of 3,066 individuals, fat-free mass decreased by 11.7 percent after bariatric surgery but by only 3.3 percent during treatment with semaglutide or tirzepatide over 24 months. Meanwhile, fat mass fell far more dramatically, by 49.7 percent in the surgical group and 18.0 percent in the medication group. Crucially, in both groups the ratio of fat-free mass to fat mass improved, meaning patients ended up with a more favorable body composition than they started with. The authors contend that this pattern, in which adipose tissue declines disproportionately while most lean tissue is preserved, is difficult to reconcile with the notion of treatment-induced muscle wasting, although they acknowledge that a treatment-specific contribution cannot be entirely excluded.

Body composition sub-studies from the major clinical trial programs reinforce the point. In the STEP trials of semaglutide and the SURMOUNT program of tirzepatide, investigators documented marked reductions in total fat mass alongside preservation of most lean mass, yielding a net improvement in the lean-to-fat mass ratio despite modest absolute declines in lean tissue. Similar findings have emerged with oral semaglutide in people with type 2 diabetes, where fat mass declined significantly while skeletal muscle index and lean body mass remained largely unchanged. Taken together, these data suggest that incretin therapies preferentially strip away the tissue that is causing harm while leaving the metabolically active machinery of muscle largely intact.

Perhaps the most provocative element of the perspective is its argument that obesity itself damages muscle quality, so that weight loss may actually improve the muscle that remains. Excess adiposity promotes the accumulation of fat within muscle fibers, chronic low-grade systemic inflammation, mitochondrial dysfunction, and reduced contractile efficiency, producing muscle that is quantitatively larger but functionally inferior. Intentional weight loss appears to reverse several of these abnormalities: even as lean mass declines modestly, reductions in intramuscular lipid infiltration and inflammation, together with improvements in oxidative capacity, may enhance the functional quality of skeletal muscle. The authors invoke a memorable formulation to capture this idea: a smaller muscle is not necessarily a weaker muscle, and may in fact be metabolically healthier and more efficient than the enlarged, fat-infiltrated muscle it replaces.

The strongest evidence against the sarcopenia hypothesis comes from measurements of what muscles actually do. Across obesity trials, incretin therapy has consistently improved exercise capacity, physical performance, and mobility rather than degrading them. Multiple STEP studies demonstrated meaningful improvements in physical functioning and obesity-specific quality of life following semaglutide treatment, outcomes that are difficult to square with clinically relevant muscle loss, which would be expected to impair rather than enhance function. Evidence from bariatric surgery points in the same direction: despite substantial reductions in lean body mass during the first postoperative year, relative muscle strength, gait speed, chair-stand performance, and overall physical function consistently improve, changes long recognized as reflecting favorable physiological remodeling. Subgroup analyses of the major obesity trials have also shown comparable efficacy and safety of incretin therapies in participants aged 65 and older compared with younger adults, supporting their use in appropriately selected older patients.

None of this means the field can afford complacency, and the authors are careful to delineate who remains genuinely at risk. Sarcopenic obesity, the coexistence of excess adiposity with impaired muscle quantity, quality, and function, is a well-recognized clinical entity associated with frailty, disability, hospitalization, cardiometabolic complications, and increased mortality, and current consensus definitions emphasize function rather than mass alone. Older adults and individuals with pre-existing sarcopenia or frailty, low muscle strength, chronic inflammatory, kidney, or cardiovascular disease, prolonged physical inactivity, or inadequate nutritional intake are inherently more vulnerable to declines in muscle health regardless of which weight-loss strategy is employed. For these populations, the authors advocate a risk-stratified approach: baseline assessment and longitudinal monitoring of muscle strength and physical performance, attention to the rate of weight loss, and individualized nutritional support, whereas patients with preserved muscle reserve can generally be followed with routine clinical care.

The practical prescriptions that follow are grounded in established evidence rather than speculation. Adequate dietary protein intake, tailored to age, renal function, and nutritional status, should accompany pharmacological weight loss, and progressive resistance exercise should be regarded as an essential component of obesity treatment rather than an optional adjunct, complemented by aerobic activity to optimize cardiometabolic health. These recommendations align with current obesity guidelines and with studies showing that resistance training attenuates lean mass loss while improving muscle strength and physical performance during intentional weight loss. The authors also situate the muscle debate within the broader risk-benefit calculus of incretin therapy, noting that semaglutide has been shown to reduce major cardiovascular events in people with overweight or obesity and established cardiovascular disease, and that recent phase 3 data demonstrate benefits in metabolic dysfunction-associated steatohepatitis. Emerging analyses suggest these cardiovascular gains may not be fully explained by the magnitude of weight loss, pointing to anti-inflammatory and direct receptor-mediated effects that extend beyond adiposity reduction.

Significant knowledge gaps remain, and the perspective is candid about them. Long-term data extending beyond the duration of current clinical trials are limited, and the effects of incretin therapies in people with established sarcopenic obesity have barely been studied. The authors call for future research to prioritize muscle quality and function over lean mass alone, to establish standardized definitions of clinically meaningful muscle loss, and to test whether combining incretin drugs with resistance exercise, nutritional optimization, and emerging anabolic agents targeting the myostatin-activin signaling pathway can further optimize body composition and functional outcomes in high-risk groups. Skeletal muscle is also an endocrine organ, releasing myokines that regulate glucose and energy metabolism across organs, so substantial loss of functional muscle tissue could carry metabolic consequences beyond strength and mobility, a consideration that keeps the question scientifically live even as the clinical picture looks reassuring.

The conceptual shift the authors propose is ultimately about how medicine should judge success in obesity treatment. The field has already moved from counting kilograms to analyzing body composition, and the next step, they argue, is to focus on patient-centered outcomes: whether treatment leaves people healthier, stronger, and more functional. By that standard, the available evidence suggests that incretin therapies are restoring physiology rather than eroding it, preferentially removing the fat that drives disease while preserving, and possibly improving, the quality of the muscle that remains. Rather than viewing every kilogram of lean tissue lost as evidence of harm, clinicians should ask the harder and more meaningful question of whether patients can move better, live longer, and feel healthier, and on current evidence, the answer for most appears to be yes, provided that protein intake, resistance exercise, and vigilant monitoring of vulnerable patients remain part of the prescription.

Subject of Research: Body composition changes and sarcopenia risk during incretin-based obesity therapy

Article Title: Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern

Article References: Koufakis, T., Tentolouris, A., Karakasis, P., Popovic, D. S., & Patoulias, D. (2026). Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern. Advances in Therapy. https://doi.org/10.1007/s12325-026-03804-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03804-z

Keywords: incretin therapy, semaglutide, tirzepatide, obesity, sarcopenia, lean body mass, body composition, skeletal muscle, resistance exercise, muscle quality, bariatric surgery, cardiometabolic health

The stakes of this comparison are enormous. Type 2 diabetes now affects an estimated 589 million adults worldwide as of 2024, a figure projected to climb to 853 million by 2050. Because the disease drives complications through both chronic hyperglycemia and the twin burdens of obesity and cardiovascular disease, contemporary treatment guidelines no longer ask simply whether a drug lowers glucose. They demand sustained reductions in hemoglobin A1c, meaningful weight reduction, cardiovascular safety, and tolerability that patients can live with for decades. Both tirzepatide and dulaglutide are once-weekly subcutaneous injections, but they work differently at the molecular level, and until now no trial had ever compared all clinically relevant doses of the two drugs simultaneously.

Dulaglutide is a selective glucagon-like peptide-1 receptor agonist, a class of drugs that mimics an intestinal hormone to boost glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. It carries hard cardiovascular outcome evidence: in the landmark REWIND trial, dulaglutide reduced major adverse cardiovascular events compared with placebo in people with type 2 diabetes. Tirzepatide, by contrast, is a first-in-class dual agonist that engages both the GIP and GLP-1 receptors, amplifying the incretin effect through two complementary hormonal pathways. Head-to-head trials had already hinted that tirzepatide’s dual mechanism translated into greater reductions in HbA1c and body weight, but individual studies compared only selected dose pairs, leaving clinicians without a comprehensive map of which specific dose delivers which specific benefit.

The research team, following Cochrane Handbook methodology and PRISMA reporting guidelines with a prospectively registered protocol, searched four major databases through the end of 2025 and identified four eligible randomized trials. Three of these were judged to carry low risk of bias across all assessed domains; the fourth, an open-label switching study, raised some concerns because participants and clinicians knew which treatment was being given. The largest trial by far was the SURPASS-CVOT cardiovascular outcomes study, which enrolled 13,165 patients with established atherosclerotic cardiovascular disease and demonstrated that tirzepatide titrated up to 15 milligrams was noninferior to dulaglutide 1.5 milligrams for the composite of cardiovascular death, myocardial infarction, or stroke over a median follow-up of roughly four years.

Using a frequentist random-effects network model, the analysts computed treatment effects and SUCRA rankings, a statistical measure of each dose’s cumulative probability of being among the most effective options. The results formed a clean dose-response gradient. For glycemic control, tirzepatide 15 milligrams ranked highest at both 12 and 24 weeks, achieving SUCRA values of 0.95 and 0.99 respectively, while dulaglutide 1.5 milligrams sat near the bottom of the efficacy rankings. At 24 weeks, tirzepatide 15 milligrams reduced HbA1c significantly more than tirzepatide 5 milligrams, and both dulaglutide 0.75 and 1.5 milligrams were associated with meaningfully smaller reductions. The differences of 0.2 to 0.4 percentage points between higher and lower tirzepatide doses are clinically meaningful, because shifts of that magnitude can move patients across standard treatment targets and delay the need for therapy intensification.

The weight findings followed the same pattern with even sharper separation. By week 16, tirzepatide 15 milligrams outperformed tirzepatide 5 milligrams by an additional 2.68 kilograms of weight loss, and the contrast against the weakest doses was dramatic: dulaglutide 0.75 milligrams and tirzepatide 1 milligram trailed the top dose by roughly 5 to 8 kilograms. Tirzepatide 15 milligrams earned a SUCRA of 0.95 for weight reduction, with the 10 milligram dose close behind, while tirzepatide 1 milligram ranked nearly last. Notably, the early weight outcomes showed substantial statistical heterogeneity, which the authors attribute to the sensitivity of short-term weight trajectories to titration schedules, baseline body mass index, diabetes duration, and transient gastrointestinal symptoms that can temporarily suppress food intake during dose escalation.

Safety told the mirror-image story. Tirzepatide 1 milligram carried the lowest risk of any treatment-emergent adverse event and of nausea, while dulaglutide 0.75 milligrams showed the lowest risks of diarrhea and vomiting. At the other end of the spectrum, both tirzepatide 15 milligrams and dulaglutide 1.5 milligrams were associated with significantly higher nausea risk compared with tirzepatide 5 milligrams. This gradient is biologically coherent: higher incretin receptor engagement intensifies slowed gastric emptying and central satiety signaling, which are precisely the mechanisms that drive both the metabolic benefits and the gastrointestinal complaints. Encouragingly, no significant differences emerged between any dose pairs for all-cause death, severe hypoglycemia, serious adverse events, pancreatitis, treatment discontinuation, or the composite cardiovascular endpoint, although the authors caution that wide confidence intervals for these rare outcomes mean the absence of statistical differences cannot be read as proof of equivalent safety.

The team stress-tested their findings with a battery of sensitivity analyses, including one that removed the dominant SURPASS-CVOT trial entirely to check whether its enormous statistical weight was distorting the network. The core conclusions held. Some outcomes, notably HbA1c at 12 weeks, early body weight change, and nausea and vomiting, proved sensitive to the inclusion of the Japanese SURPASS J-mono trial, which compared tirzepatide against the 0.75 milligram dulaglutide dose approved in Japan rather than the 1.5 milligram standard used elsewhere. Inconsistency testing using both design-by-treatment interaction models and node-splitting found no meaningful disagreement between direct and indirect evidence for most outcomes, lending credibility to the network’s internal structure.

The clinical implications are refreshingly practical. For patients whose primary goals are maximal HbA1c reduction and weight loss, the data support escalating to tirzepatide 10 or 15 milligrams when tolerability permits, with an expected stepwise advantage over lower doses and over any dulaglutide regimen. For patients whose priority is gastrointestinal tolerability, starting at lower doses such as dulaglutide 0.75 milligrams or tirzepatide 1 milligram remains a reasonable strategy, accepting more modest metabolic gains and possible later intensification. The findings also reinforce the results of the SURPASS-SWITCH trial, which showed that patients inadequately controlled on submaximal dulaglutide achieved greater HbA1c and weight improvements by switching to tirzepatide than by pushing the dulaglutide dose higher. An important interpretive caveat applies to the early time points: many participants assigned to the highest tirzepatide doses were still in protocol-mandated dose escalation at weeks 12 and 16, meaning the full maintenance-dose effects may be even larger than these figures suggest.

The authors are candid about the limitations. Only four trials informed the network, several dose nodes rested on sparse comparisons, and long-term durability, late adverse events, and sustained discontinuation could not be assessed because later time points were not consistently reported across trials. Some data were digitized from published figures, introducing the possibility of minor extraction error despite independent double-checking. Still, within those constraints, the analysis delivers something no single trial could: a unified, dose-level ranking of the two most widely used once-weekly injectable therapies for type 2 diabetes. The message for the millions of patients and their clinicians navigating this decision is one of individualized titration, balancing the escalating metabolic rewards of higher tirzepatide doses against the dose-related gastrointestinal costs, with the reassurance that cardiovascular safety appears preserved across the spectrum.

Subject of Research: Comparative efficacy and safety of tirzepatide versus dulaglutide doses in type 2 diabetes

Article Title: Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials

Article References: Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Bahnasy, S., Eladawi, S., Abdelaziz, M., Iyad, K., Kandil, A. H., Zinhom, K., Mohamed, M. R., Abdulhay, H., Turkman, M., Abdelazeem, B., & Fonarow, G. C. (2026). Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials. Endocrinology, Diabetes & Metabolism, 9(5), Article e70313. https://doi.org/10.1002/edm2.70313

Image Credits: AI Generated

DOI: 10.1002/edm2.70313

Keywords: tirzepatide, dulaglutide, type 2 diabetes, network meta-analysis, HbA1c, weight loss, GLP-1 receptor agonist, GIP, cardiovascular outcomes, gastrointestinal adverse events, dose-response, incretin therapy

The analysis, conducted according to PRISMA 2020 standards, drew its evidence from the major Phase 3 programs that defined the modern incretin era: SURMOUNT, testing tirzepatide; STEP, testing injectable semaglutide; SCALE, testing liraglutide 3.0 mg; and OASIS, testing oral semaglutide. From an initial pool of 878 records, independent reviewers narrowed the field to 19 randomized controlled trials meeting strict criteria, including a minimum duration of 12 weeks and standardized body composition or nutritional laboratory measurements. High-potency therapy was defined as any agent or dose producing at least 10 percent mean total body weight reduction, a threshold met by all tirzepatide doses, injectable semaglutide at 1.0 mg or above, and oral semaglutide 50 mg. Liraglutide 3.0 mg was classified as a moderate-potency comparator but retained because the SCALE program remains the only Phase 3 dataset with longitudinal pancreatic enzyme measurements.

The mechanistic foundation of the findings lies in the sheer magnitude of caloric suppression these drugs produce. Once-daily oral semaglutide 50 mg reduced energy intake by a relative 39.20 percent by week 20, translating to a deficit of roughly 1009 kilojoules, about 241 calories, during a single ad libitum lunch compared with placebo. Across the synthesized trials, metabolic models estimated daily energy deficits reaching 1200 kilocalories from baseline, while tirzepatide 15 mg produced a consistent 348.40 kilocalorie per day reduction. Meta-analysis of continuous intake data confirmed this suppression was statistically robust. Critically, these deficits occurred alongside shifts in food preference: participants on tirzepatide showed significant decreases in 10 of 12 food preference categories, blunting desire for high-fat and high-sugar items. The hedonic blunting that helps patients eat less may simultaneously suppress the biological hunger signals that normally correct for emerging nutrient gaps.

Body composition data revealed a second dimension of concern. Across drug classes, fat-free mass, the non-adipose component of body weight that includes muscle, bone, organs, and fluids, declined significantly. Tirzepatide 15 mg was associated with a mean fat-free mass reduction of 1.60 kg, representing 14.30 percent of total weight lost, while semaglutide 1.0 mg produced a 0.80 kg decline constituting 11.60 percent of weight reduction. The researchers emphasize that fat-free mass is not synonymous with skeletal muscle mass, and only one mechanism-of-action study reported appendicular lean mass as a muscle proxy. Even so, the proportional loss of lean tissue raises the prospect of sarcopenic obesity, a condition combining reduced muscle mass with metabolic dysfunction. The risk is sharpened by the finding that 7.26 percent of participants crossed a body mass index below 22 kg/m2, a threshold at which clinical protocols recommend modifying intake to prevent physical frailty.

The contrast between clinical reporting and laboratory reality forms the analytical centerpiece of the review. Pooled analysis of MedDRA-coded malnutrition events across the SURMOUNT 1-4 trials produced a non-significant risk ratio of 2.38, suggesting standard adverse event capture missed most nutritional deterioration. Total lymphocyte count below 910 per microliter, a marker independently associated with impaired immune function, delayed wound healing, and increased infection susceptibility, appeared in 2.90 percent of active therapy participants, nearly double the placebo rate, with a statistically significant risk ratio of 1.64. Meanwhile, 0.38 percent of tirzepatide-treated participants reached an underweight classification during treatment, and investigator-reported vitamin deficiencies involving vitamin D, B12, and folate occurred in 0.99 percent, though none of the original protocols screened for these systematically at predetermined intervals.

Secondary metabolic stressors add another layer of physiological complexity. Pooled SCALE data documented a mean 31 percent increase in pancreatic lipase and 7 percent increase in amylase following liraglutide treatment, elevations that appeared early, persisted during therapy, were dose-independent, and reversed upon drug cessation. Although 12 cases of acute pancreatitis were confirmed in liraglutide arms, a 0.4 percent incidence, the positive predictive value of enzyme elevations alone was below 1 percent, indicating these biomarkers more likely represent subclinical pancreatic stress than acute inflammation. Whether comparable enzyme dynamics occur with tirzepatide or injectable semaglutide remains unknown, because neither the SURMOUNT nor STEP programs included pancreatic enzyme monitoring. Persistent subclinical pancreatic stress could theoretically introduce a malabsorptive component, potentially compromising fat-soluble vitamin status even in patients with adequate intake.

Individual variability in baseline physiology may determine who is most vulnerable. Deep-phenotyping research describes a ‘Calories to Satiation’ trait ranging from 140 to 2166 kilocalories among adults with obesity, and high-potency incretins may amplify this gut-brain axis signal to its maximum effect. People who already reach satiation at low caloric intakes could ‘overshoot’ intended restriction, a concern compounded by sex differences, since women generally reach satiation at lower energy intakes than men. In trials with predominantly female enrollment, such as SURMOUNT-1 at 67 percent and STEP 1 at 74 percent female, the observed magnitude of lean mass loss may partly reflect this lower baseline caloric threshold. Bone health introduces a further unmeasured dimension: rapid weight loss removes the mechanical loading stimulus that sustains bone mineral density in obesity, and bariatric surgery studies document significant bone loss within 12 to 24 months. No included trial measured bone density, leaving the skeletal consequences of drug-induced weight loss entirely unquantified.

To translate these findings into clinical practice, the researchers propose a Tiered Stepped-Care Algorithm built on the 1200 kilocalorie daily deficit as the mechanistic anchor. Step one mandates baseline screening for albumin, total lymphocyte count, and vitamin D to identify pre-existing vulnerabilities. Step two requires periodic monitoring of the deficit threshold alongside body composition shifts to detect excessive lean mass attrition. Step three activates intensive intervention, with immediate referral for Medical Nutrition Therapy, when serum albumin falls below 3.3 g/dL or total lymphocyte count drops below 910 per microliter. The framework mirrors nutritional oversight long considered standard for bariatric surgery patients, a population whose weight loss trajectories are comparable in magnitude to those produced by maximum-dose tirzepatide, which achieved 22.5 percent total body weight loss over 72 weeks in SURMOUNT-1.

The authors acknowledge important limitations. The original Phase 3 programs were designed to demonstrate weight loss efficacy and cardiometabolic safety, not nutritional outcomes, so reliance on post-hoc analyses likely underestimates true malnutrition prevalence. The 12-week minimum duration criterion may have excluded shorter mechanistic studies, the predominantly East Asian population in SURPASS-AP-Combo, with lower baseline body mass indices, limits generalizability to Western cohorts, and publication bias could not be excluded from secondary endpoints. Quality assessment using the Cochrane Risk-of-Bias tool found low risk across all major domains for the included programs, and Egger regression detected no significant publication bias for the primary outcome. Future trials, the researchers argue, should incorporate pre-specified dual-energy X-ray absorptiometry monitoring, serum micronutrient panels, fecal elastase testing, head-to-head comparisons in adults aged 65 and older with sarcopenia and bone density as co-primary outcomes, and follow-up of at least two years. Sustained weight reduction remains a legitimate therapeutic goal, the analysis concludes, but the data suggest it should no longer be pursued without the nutritional surveillance needed to protect the physiological integrity of the millions of patients now taking these medications.

Subject of Research: Systematic review and meta-analysis of malnutrition risk, energy restriction, and lean mass loss in high-potency incretin therapy

Article Title: A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy

Article References: Ampofo, E., Apprey, C., Amoako, M., & Turkson, F. D. (2026). A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy. Obesity Science & Practice, 12(5), Article e70188. https://doi.org/10.1002/osp4.70188

Image Credits: AI Generated

DOI: 10.1002/osp4.70188

Keywords: incretin therapy, semaglutide, tirzepatide, liraglutide, malnutrition, fat-free mass, weight loss, obesity, GLP-1 receptor agonists, nutritional monitoring, sarcopenia, meta-analysis